AdvaMed State Policy Briefing: PFAS – Background, Basics, and State Policy

This week, in a letter to Senate Majority Leader Chuck Schumer, AdvaMed President and CEO Scott Whitaker underscored the critical importance of passing a tax provision that allows small businesses to deduct their research and development expenses in the year the expense was incurred. AdvaMed, the world’s largest trade association representing medical technology companies, supports the provision, which until 2022, encouraged small companies and startups to continue investing in R&D, the lifeblood of these primarily pre-commercial companies.

Today, Zach Rothstein, Executive Director of AdvaMedDx, testified before the House Energy and Commerce Committee, Subcommittee on Health during a hearing on diagnostic test regulation and FDA’s proposed laboratory developed test (LDT) rule.

Former U.S. Senator Richard Burr of North Carolina joined me on the Medtech POV podcast to share his perspective on policy and leadership. Having served in the U.S. House and Senate for nearly three decades, including tenure as Ranking Member of the Senate Committee on Health, Education, Labor and Pensions (HELP), he’s an expert on health care policy. He also has a historical perspective that anyone involved in health-care policy should value. 

Scott Whitaker, President and CEO of AdvaMed, the Medtech Association, sent a letter to CMS Administrator Chiquita Brooks-LaSure outlining industry disappointment in the lack of a finalized rule for Transitional Coverage for Emerging Technology.

Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the potential government shutdown and the impact it could have on patients: 

Today, AdvaMed, the Medtech Association, released the newest episode of Medtech POV with Scott Whitaker, featuring a conversation with former Senator Richard Burr of North Carolina.

In testimony today before the U.S. House of Representatives Committee on Small Business, Dr. Lishan Aklog urged Congress and the executive branch to consider the dire consequences for patients and medtech innovation if proposals further regulating the most prevalent method of sterilizing medical technology go forward without significant changes.

Today, AdvaMed, the Medtech Association, announced Kelvyn Cullimore, President and CEO of BioUtah, will serve as the next chair of the State Medtech Alliance (SMTA). The Alliance is a consortium of state and regional trade associations representing their local medical technology companies. Cullimore succeeds Dean Paranicas, who previously served as President and CEO of the  HealthCare Institute of New Jersey (HINJ).